ASCO 2024
Prognostic value of ctDNA in therapeutic strategies; Endocrine therapy in ER-low BC
monarchE, ER-low
ASCO 2024
Prognostic value of ctDNA in therapeutic strategies;…
A-BRAVE, PEARLY
ASCO 2024
Immunotherapy makes a difference in survival in eTNBC
FLEX (MammaPrint)
ASCO 2024
The search for predicitve biomarkers continues
A-BRAVE
ASCO 2024
Avelumab in early TNBC
ASCO 2024
AI for the prediction of disease progression
ASCO 2024
Adjuvant endocrine therapy for ER-low EBC
I-SPY2.2
ASCO 2024
Personalized neoadjuvant therapy for high-risk breast…
monarchE
ASCO 2024
ctDNA important for HR+ eBC?
monarchE
ASCO 2024
ctDNA analysis in monarchE
NATALEE
ASCO 2024
Advantage for node-negative patients
NATALEE
ASCO 2024
Ribociclib is also effective in N0 HR+/HER2− EBC
A-BRAVE
ASCO 2024
Avelumab nel TNBC precoce
PATRICIA
ASCO 2204
One step closer to chemo-free therapy for HR+/HER2+…
Destiny-Breast06
ASCO 2024
Expanding T-DxD use to HER2 ultra-low - the success…
INAVO120
ASCO 2024
Improvement for firstline treatment for patients with…
Young-PEARL, Post Monarch
ASCO 2024
Reassuring and clarifying new data for CDK4/6…
ASCO 2024
Heterogenity of ER+ disease
Young-PEARL
ASCO 2024
New data on the omission of chemotherapy in young…
ASCO 2024
ER-low: endocrine therapy necessary after all?
PATRICIA
ASCO 2024
Is there still a place for endocrine therapy in HER2+…
DE-REAL
ASCO 2024
Systemic therapy of HER2+ patients with brain…
EMERALD
ASCO 2024
Eribulin, Trastuzumab, Pertuzumab in 1stL HER2+ mBC
PATRICIA
ASCO 2024
Triple positive mBC - chemotherapy unnecessary?
RxPONDER
ASCO 2024
Responder premenopausal
TBCRC049
ASCO 2024
Leptomeningeal metastases in HER2+ mBC
SACI-IO HR+
ASCO 2024
Novel ADC-ICI combination therapy
ADC - Clinical Science Symposium
ASCO 2024
The ADC revolution continues - ctDNA takes the next…
PRIMED
ASCO 2024
Decreasing SG related toxicity with profilatic G-CFS
Destiny-Breast06
ASCO 2024
Expanding use of T-DxD in HER2low and HER2 ultra-low…
Destiny-Breast07
ASCO 2024
T-DXD continues its impressive track record for MBC…
DESTINY-Breast06
ASCO 2024
Ultra low - ultra good?
Destiny-Breast 06
ASCO 2024
Broaden T-DXD as therapy standard for HER2low and…
DESTINY-Breast07
ASCO 2024
HER2+ mBC 1stL T-Dxd
OptiTROP-Breast01
ASCO 2024
Sacituzumab tirumotecan - a new powerful ADC for…
Destiny Breast 03
ASCO 2024
Important OS benefit with T-Dxd in HER2+ mBC
Young-PEARL
ASCO 2024
CDK4/6i effective in premenopausal patients as well
INAVO120
ASCO 2024
First-line inavolisib/placebo + palbociclib +…
postMonarch
ASCO 2024
CDK4/6 rechallenge
INAVO120
ASCO 2024
Already more in the 1stL?
postMONARCH
ASCO 2024
Treatment beyond progression for CDK 4/6i
PATRICIA
ASCO 2024
Chemo-free regimen in HER2+ luminal breast cancer
PATRICIA
ASCO 2024
Endocrine therapy with Palbociclib + Trastuzumab
PATRICIA
ASCO 2024
Chemo-free, CDK4/6 inhibitor-based combination active…
INAVO120
ASCO 2024
INAVO120 - updated results
postMonarch
ASCO 2024
CDK4/6 rechallenge
PATRICIA
ASCO 2024
Le traitement endocrinien a-t-il encore sa place dans…
PRIMED
ASCO 2024
Disminución de la toxicidad relacionada con la OS con…
OptiTROP-Breast01
ASCO 2024
Sacituzumab tirumotecan – nowy aktywny koniugat w…
PATRICIA
ASCO 2024
C'è ancora posto per la terapia endocrina nel BC HER2+?
PATRICIA
ASCO 2024
Leczenie bez chemioterapii, oparte na inhibitorze…
INAVO120
ASCO 2024
INAVO120: risultati aggiornati
PATRICIA
ASCO 2024
Regime senza chemioterapia nel carcinoma mammario…
Destiny Breast 03
ASCO 2024
Importante beneficio en la supervivencia global con…
ASCO 2024
La révolution de l'ADC se poursuit / ctDNA franchit une…
Destiny-Breast06
ASCO 2024
Espansione dell'uso di T-DxD nelle pazienti con…
PROMISE
ASCO 2024
PSMA-PET CT: Ready for clinical practice or a PROMISE…
EMBARK, PRESTO
ASCO 2024
Focus on Quality of Life
MAST, MANCAN
ASCO 2024
Is the metformin story over? How to treat HFNS…
CHAARTED2, CYCLONE 2, PSMAfore
ASCO 2024
Interesting data - but not practice changing
EMBARK
ASCO 2024
Deciphering EMBARK: Exploring Enzalutamide's Impact on…
PSMA-fore
ASCO 2024
RCT in mCRPC
JNJ-6420
ASCO 2024
Radionukleotides - the next step forward
PROMISE
ASCO 2024
Unveiling the Potential: PSMA-PET in Prostate Cancer…
ALLIANCE
ASCO 2024
Unlocking Insights: The ALLIANCE Trial redefining…
COBRA
ASCO 2024
The evolving role of PSMA-PET with new agents
STAMPEDE
ASCO 2024
mCRPC: Who benefits from which measures?
EMBARK
ASCO 2024
EMBARK demonstrates the importance of HRQoL benefit in…
CHAARTED2
ASCO 2024
Exploring the CHAARTED TRIAL: Optimizing Treatment…
ARASENS
ASCO 2024
ARASENS Post hoc analysis: Therapy after progression
EMBARK
ASCO 2024
EMBARK: Quality of Life
CYCLONE 2
ASCO 2024
mCRCP CYCLONE 2 study
PSMAfore
ASCO 2024
Important QoL data
EV-302, EV-101,EV-201,EV-301, Checkmate 901
ASCO 2024
EV-Pembro shows consistent outcome - caution with…
Sure 01,02, TROPICS-04
ASCO 2024
Perioperative treamtent in MIBC - new data for the use…
CheckMate 901
ASCO 2024
What to do with Cis Gem Nivo?
ULTIMA
ASCO 2024
Treatment of urachal carcinoma
SWOG S1600
ASCO 2024
Effect of an immune diet on the outcome after radical…
ASCO 2024
MI-UC - News from EVP standard
JAVELIN Bladder 100
ASCO 2024
Biomarkers and long-term outcomes in pts with low tumor…
HERCULES
ASCO 2024
ASCO 2024: Time for the rare GU tumors?
KEYNOTE-361
ASCO 2024
ctDNA as a biomarker in metastatic bladder cancer
ULTMA
ASCO 2024
Modified FOLFIRINOX therapy as a good option for…
ASCO 2024
Quality of life not affected by i. v. Pembro
SURE-01/02
ASCO 2024
Preoperative use of sacituzumab govitecan
EV-302, EV-201, CheckMate 901, TROPICS-04, SURE-01/02
ASCO 2024
ASCO24: Bladder cancer highlights
SURE-01/02
ASCO 2024
The Role of Topoisomerase Inhibitors in the…
SURE-01/02
ASCO 2024
Interim analysis of the SURE-01/02 study
SURE-01/02
ASCO 2024
The future of sacituzumab govitecan
JAVELIN, Bladder 100
ASCO 2024
Biomarcadores y resultados a largo plazo en pacientes…
SURE-01/02
ASCO 2024
El papel de los inhibidores de topoisomerasa en el…
EV-302, EV-201, CheckMate 901, TROPICS-04, SURE-01/02
ASCO 2024
ASCO24: Bladder cancer highlights
SURE-01/02
ASCO 2024
El futuro de sacituzumab govitecan
ASCO 2024
ASCO 2024: momento para los tumores GU poco frequentes?
CARAT
ASCO 2024
Supportive real-world data from German research…
ASCO 2024
Evaluating risk criteria and monotherapy in mRCC
KEYNOTE-426, CLEAR
ASCO 2024
Advancing our understanding of biological mechanisms…
IMmotion101
ASCO 2024
Advancing Our Understanding of Biological Mechanisms…
ASCO 2024
Combination is superior to monotherapy - how do we…
ASCO 2024
DFF332 a novel HIF inhibitor
ASCO 2024
Metastasized chromophobe RCC
IMDC
ASCO 2024
Treatment of favorable prognosis mRCC patients:…
ASCO 2024
Combination therapies for chromophobe renal cell…
KEYNOTE426, CLEAR
ASCO 2024
The search of the ideal biomarker in advanced renal…
KEYNOTE 426, CLEAR
ASCO 2024
Biomarker analysis of KN426 & CLEAR
IMmotion010
ASCO 2024
KIM-1 - old wine in new bottles
ASCO 2024
New HIF inhibitor in clear cell RCC
ASCO 2024
nccRCC
ASCO 2024
New IMDC risk group - very favorable
IMmotion 101
ASCO 2024
Adjuvant KIM-1 as prognostic & predictive biomarker
CLEAR, KEYNOTE426
ASCO 2024
The never ending saga of biomarkers
CheckMate 9ER
ASCO 2024
NIVO+CABO: significantly longer therapy-free time
LITESPARK-013
ASCO 2024
Belzutifan in earlier lines in advanced ccRCC
IMotion101
ASCO 2024
KIM-1: Will have a major impact
IMmotion010
ASCO 2024
Another breakthrough perioperative
IMDC
ASCO 2024
Tratamiento del cancer renal avanzado de pronostico…
KEYNOTE426, CLEAR
ASCO 2024
La busqueda del marcador ideal en el cancer renal…
CheckMate 816, CheckMate 77T, AGEAN
ASCO 2024
Adjuvant therapy: how to identify patients who will…
LAURA
ASCO 2024
End of the story in EGFRm disease?
CheckMate, 77T AEGEAN
ASCO 2024
Perioperative chemotherapy and N2 status
LAURA
ASCO 2024
Gamechanger in EGFR-mutated NSCLC
ctDNA-Lung-DETECT
ASCO 2024
Liquid biopsy in curative situation
LAURA
ASCO 2024
Osimertinib improves PFS in stage III
LAURA
ASCO 2024
Stadium III EGFR+: now permanently Osimertinib?!
CheckMate 816
ASCO 2024
CheckMate 816: 4-year update
KEYNOTE-799
ASCO 2024
4-year efficacy of Keynote-799 and ctDNA
AEGEAN
ASCO 2024
Confirmed efficacy of periop IO in N2 R-NSCLC
LAURA
ASCO 2024
Early change in SOC in EGFR+ LD-NSCLC
ADAURA
ASCO 2024
ctDNA predicts outcome in patients treated with…
CheckMate 816
ASCO 2024
4y follow-up of CheckMate 816
LAURA
ASCO 2024
Cambio temprano en el tratamiento estándar del EGFR+…
CheckMate 816
ASCO 2024
4y follow-up de CheckMate 816
LAURA
ASCO 2024
Le traitement adjuvant par osimertinib apres CTRT : …
KRYSTAL-12, KROCUSn CodeBreaK 101
ASCO 2024
KRAS in NSCLC - a lot to come
EVOKE-01, ICARUS-LUNG01, OptiTROP-Lung01
ASCO 2024
TROP2-targeting ADCs: where a we heading?
MARIPOSA, PALOMA-3, HARMONi-A
ASCO 2024
Update for EGFR-positive NSCLC
CROWN
ASCO 2024
Lorlatinib with extraordinary data in ALK + NSCLC
ASCO 2024
Telehealth is just as effective as a face-to-face visit…
CROWN
ASCO 2024
ALK+ NSCLC - CROWN revisited
KRYSTAL-12
ASCO 2024
KRASG12C - the story continues
LAURA, PALOMA-3, KRYSTAL-12, ADRIATIC
ASCO 2024
ASCO 2024 highlights
PALOMA-3
ASCO 2024
Subcut amivantamab - the future
EVOKE-01, OptiTROP-Lung01
ASCO 2024
ADCs - moving landscapes. Subgroups remain to be…
KRYSTAL-12
ASCO 2024
Confirmed efficacy of adagrasib in KRASG12C
MARIPOSA, PALOMA-3
ASCO 2024
EGFR+ NSCLC - amivantamab-based combination therapy
KRYSTAL-12
ASCO 2024
KRAS building on single agent therapy
NRG-LU002
ASCO 2024
The end for local therapy for oligometastatic disease
CROWN
ASCO 2024
Lorlatinib convincing in ALK mutation 1st line
CheckMate 9LA
ASCO 2024
Confirmed efficacy in PD-L1 negativity - CheckMate 9LA
KRYSTAL-12
ASCO 2024
Adagrasib for KRASG12C mutation 2nd line
ASCO 2024
BAY297088 - Promising Her2-Inhibitor in NSCLC
LAURA, PALOMA-3, KRYSTAL-12, ADRIATIC
ASCO 2024
ASCO 2024 highlights
KRYSTAL-12
ASCO 2024
KRASG12C - het verhaal gaat verder
NRG-LU002
ASCO 2024
Het einde van lokale therapie voor oligometastatische…
ASCO 2024
La télésanté est aussi efficace qu'une consultation…
LAURA, PALOMA-3, KRYSTAL-12, ADRIATIC
ASCO 2024
ASCO 2024 highlights
ASCO 2024
BAY297088 - Inhibiteur Her2-Inhibitor dans le NSCLC
ADRIATIC
ASCO 2024
Redefining SOC in LD-SCLC: Durvalumab as consolidation…
DeLLphi-301
ASCO 2024
Tarlatamab shows activity in patients with brain…
ADRIATIC
ASCO 2024
Maintenance with durvalumab is the new SOC after…
ADRIATIC
ASCO 2024
LD-SCLC: What´s about PCI?
ADRIATIC
ASCO 2024
Finally, change for LS-SCLC
ADRIATIC
ASCO 2024
New SoC for LD-SCLC
ADRIATIC
ASCO 2024
Le traitement d'entretien avec le durvalumab est le…
ADRIATIC
ASCO 2024
Tot slot, verandering voor LS-SCLC
BEAT-meso
ASCO 2024
Unexpected results; which subgroup could benefit from…
BEAT-meso
ASCO 2024
Harsh to beat
BEAT-meso
ASCO 2024
Chemo-immuno in mesothelioma - update
BEAT-meso
ASCO 2024
Difícil de superar
RELATIVITY-048
ASCO 2024
Is the triplet ready for phase 3?
KEYNOTE-942
ASCO 2024
Personalized mRNA-vaccination: Practice changer of the…
EBIN
ASCO 2024
Is the induction treatment the new strategy for…
PIVOTAL
ASCO 2024
Stimulating new combination of two antibody-cytokine…
COMBI-AD
ASCO 2024
10 years follow up - immunotherapy for BRAF-mutated…
NADINA
ASCO 2024
Is adjuvant treatment still standard in macroscopic,…
EBIN
ASCO 2024
No differences in PFS between the two study arms
NADINA
ASCO 2024
Progress in neoadjuvant therapy with IO
IGNYTE
ASCO 2024
Vaccine in combination with nivolumab for PDL1…
PIVOTAL
ASCO 2024
Neoadjuvant intratumoral therapy with Daromun in…
COMBI-AD
ASCO 2024
Adjuvant therapy with dabrafenib and trametinib - final…
TRICOTEL
ASCO 2024
A new therapy benchmark for brain-met melanoma patients
ASCO 2024
Promising activity of brenetafusp in PD-L1 refractory…
COMBI-AD
ASCO 2024
Impactful studies from ASCO 24 II: Combi-AD
ASCO 2024
Impactful studies from ASCO 24 III: Cell-therapy
COMBI-AD
ASCO 2024
Longterm survival after adjuvant targeted therapy
REALTIVIY-048
ASCO 2024
A new triplet for metastatic melanoma
IOV-COM-202
ASCO 2024
TIL therapy for metastatic melanoma
PIVOTAL
ASCO 2024
Intralesional therapy with Daromun
ASCO 2024
Identifying patients with longterm benefits during…
COMBI-AD
ASCO 2024
Survival data for TT with dabrafenib and trametinib
KEYMAKER-U02A
ASCO 2024
Emerging rescue therapies for PD1 refractory melanoma
NADINA
ASCO 2024
Neoadjuvant immunotherapy treatment for melanoma
RELATIVITY-048
ASCO 2024
Triple checkpoint blockade - a new approach?
NADINA
ASCO 2024
Impactful studies from ASCO 24 I: NADINA
IGNYTE
ASCO 2024
New oncolytic immunotherapy (RP1) after PD-1 failure
NADINA
ASCO 2024
Consolidation of the use of IO in clinically detectable…
KEYNOTE-942
ASCO 2024
3-year update on mRNA vaccines in melanoma
KEYNOTE-942
ASCO 2024
mRNA vaccine plus pembrolizumab in adjuvant therapy
Relativity-048
ASCO 2024
Promising Results: Triple combination therapy in…
ASCO 2024
Lentigo maligna therapy
Relativity-048
ASCO 2024
Risultati promettenti: Tripla terapia di combinazione…
NADINA
ASCO 2024
Consolidación del uso de IO en melanoma en estadio III…
ASCO 2024
Prometedora actividad de brenetafusp en melanoma…
EBIN
ASCO 2024
No hubo diferencias en la PFS entre los dos brazos del…
ASCO 2024
New therapeutic approaches: Get over PD1 resistances?
ASCO 2024
Encouraging developmental IO-options
ASCO 2024
New insights in localized HNSCC
ASCO 2024
New perspectives in HPV+ r/m HNSCC
innovaTV 207
ASCO 2024
New MOA in r/m HNSCC
NEO
ASCO 2024
De-escalation in ovarian cancer?
KEYVIBE-005
ASCO 2024
New idea: anti-digest for EC?
BrUOG 354
ASCO 2024
Clear cell carcinomas benefit from IO therapy
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!